ClinicalTrials.gg
CompletedNCT02681172Updated Oct 9, 2026Results posted

Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD

A Phase 4 interventional study of Neuraceq (florbetaben 18F) and PET in Alzheimer's Disease (AD), sponsored by Lantheus Biosciences Ltd.. Completed at 1 site in France. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Lantheus Biosciences Ltd. (part of Lantheus Holdings, Inc.) · Phase 4, Interventional, and Health services research

Updated Oct 9, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
218
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 438 studies in Alzheimer Disease with a site in France — 80 open to participants now, 97 under way, 19 of them phase 3. Alzheimer Disease · France.

Enrollment
143rd of 342
218 · median 154
Started
2015
with 19 others
Phase 4
7 of 438
2 open now
Registered
205th of 438
by date

Among the 438 studies in Alzheimer Disease with a site in France, this one is the 143rd largest by enrollment of the 342 interventional ones that give a count, is one of 20 that started in 2015, is one of 7 in phase 4, and was the 205th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

80 of the 438 studies in Alzheimer Disease with a site in France are open now. Recruiting first, the newest first:

75 more — sign in →

All 80 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 438 studies in Alzheimer Disease with a site in France, or all of them as a file.
02

Study summary

This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and functional impairment, but in whom:

  1. lumbar puncture was not feasible for medical conditions
  2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating physicians
  3. lumbar puncture (LP) was refused by the patient
Read the detailed description

It will be conducted in an outpatient setting at the tertiary memory clinics (CMRR) in France in patients with a preliminary diagnosis based on the completion of a prior, full diagnostic workup, not more than 12 months previously - which could include, but will not be limited to brain imaging if needed (magnetic resonance imaging (MRI) or computed tomography (CT)), neuropsychological evaluation including a Mini-Mental Status Examination (MMSE), CSF examination and other examinations according to "Haute Autorité de santé" (HAS, National Authority of Health, France) Recommendations - and in whom:

  1. lumbar puncture was not feasible for medical conditions
  2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating physicians
  3. lumbar puncture (LP) was refused by the patient

For all subjects the study will comprise 3 outpatient clinic visits to record information on previous work ups and to perform the FBB Positron Emission Tomography (PET) scan (Visit 1: screening/ baseline, Visit 2: PET scan, Visit 3: subject informed on the FBB PET scan result).

At Visit 1, the initial diagnosis based on previous work up will be collected and rated on a five-point Likert confidence scale by the Physician.

At Visit 2, the FBB PET scan will be performed. Adverse events will be reported during the exam and up to 7 days after the PET procedure.

At Visit 3, based on the amyloid PET scan results, change of diagnosis will be collected, in addition to physician confidence.

03

Conditions studied

  • Alzheimer's Disease (AD)

Browse trials for

Keywords

  • CSF
  • Alzheimer's Disease (AD) and related dementia
  • HAS recommendations
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients being evaluated for Alzheimer disease and related dementias according to the HAS recommendations (atypical dementia, early onset and rapid progressive dementia)
  • Patients who have previously been evaluated for AD and related dementias to whom a CSF examination was recommended in the last 12 months, but lumbar puncture was or refused or CSF results were ambiguous, or
  • Patients currently being evaluated for AD and related dementias to whom a CSF examination is recommended but lumbar puncture is contraindicated or refused
  • Patients have a study partner who is willing and able to accompany him/her to all clinic visits for the duration of the protocol
  • Patients able to complete all clinical visits according to the protocol
  • Patients able to tolerate a 20-minute FBB PET scan
  • Patient or legal representative to provide for study participation, visits and data source verification.

Exclusion criteria

Exclusion Criteria:

  • The subject had a previous beta amyloid imaging scan
  • Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol
  • Is currently receiving any pharmaceutical product or has participated in a clinical trial with an investigational pharmaceutical product within 30 days prior to screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study
  • For females of childbearing age, a positive pregnancy test
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    Neuraceq (florbetaben 18F) PET scan

    A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject. The applied florbetaben radioactive dose will be ± 20%.

    Drug: Neuraceq (florbetaben 18F) · Procedure: PET

Interventions

  • Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.

    Also known as: FBB

  • ProcedurePET

    A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.

    Also known as: Positron Emission Tomography

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes

    The Physician's diagnosis was assessed before and after FBB PET scan. The initial Physician's diagnosis was collected before the PET scan, at Visit 1, based on key diagnostic results of current or previous workup. After the PET scan, the final Physician's diagnosis was collected at Visit 3, based on the amyloid PET scan results.

    Time frame: Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)

Secondary outcomes

  1. Number of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3

    The Physician's diagnostic confidence was rated on a five-point Likert scale before and after FBB PET scan. Likert scales consisted of the categories: "very weak", "weak", "moderate", "high", and "very high".

    Time frame: Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)

  2. Number of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes

    For all subjects, concomitant medications were reported and any change of the management plan (e.g. new medications initiated, medications withdrawn, additional diagnostic tests ordered, referred to another specialist) was noted.

    Time frame: Visit 1 (baseline evaluation) and Visit 3 (up to 3 months later)

  3. Number of Subjects With Positive FBB PET Scan

    PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.

    Time frame: Visit 3 (up to 6 months after baseline evaluation)

  4. Number of Subjects With Negative FBB PET Scans

    PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.

    Time frame: Visit 3 (up to 6 months after baseline evaluation)

  5. Number of Subjects With Contraindicated or Failed Lumbar Puncture

    Number of subjects with contraindicated or failed LP (anticoagulant therapy, thrombocytopenia, lumbar puncture failed, spinal problems)

    Time frame: Visit 1 (baseline evaluation)

  6. Number of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician

    Non-contributory CSF results (ambiguous CSF result, CSF result inconsistent with clinical information, uninterpretable CSF result for technical reasons)

    Time frame: Visit 1 (baseline evaluation)

  7. Number of Subjects Who Refused Lumbar Puncture.

    Time frame: Visit 1 (baseline evaluation)

07

Results

Posted Nov 2, 2018

Participant flow

This was a Phase IV, multi-center study which was conducted in an outpatient setting documenting routine clinical care in the Centres Mémoire Ressources et Recherches (CMRR). Subjects were recruited in 18 active centers in France.

Participant flow — Overall Study
MilestoneNeuraceq (Florbetaben 18F) PET Scan
Started218
Safety analysis set205
Full analysis set205
Per protocol set205
Completed205
Not completed13

Outcome measures

PrimaryNumber of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes

The Physician's diagnosis was assessed before and after FBB PET scan. The initial Physician's diagnosis was collected before the PET scan, at Visit 1, based on key diagnostic results of current or previous workup. After the PET scan, the final Physician's diagnosis was collected at Visit 3, based on the amyloid PET scan results.

Time frame:
Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)
Reported as:
Count of participants · Participants
Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes
ParticipantsSafety Analysis Set
Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes137
SecondaryNumber of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3

The Physician's diagnostic confidence was rated on a five-point Likert scale before and after FBB PET scan. Likert scales consisted of the categories: "very weak", "weak", "moderate", "high", and "very high".

Time frame:
Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)
Reported as:
Count of participants · Participants
Number of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3
ParticipantsSafety Analysis Set
Number of Subjects With Improved Level of Physician Confidence in Diagnosis at Visit 3167
SecondaryNumber of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes

For all subjects, concomitant medications were reported and any change of the management plan (e.g. new medications initiated, medications withdrawn, additional diagnostic tests ordered, referred to another specialist) was noted.

Time frame:
Visit 1 (baseline evaluation) and Visit 3 (up to 3 months later)
Reported as:
Count of participants · Participants
Number of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes
ParticipantsSafety Analysis Set
Number of Participants With a Change of Management Plan Comparing Pre- and Post-scan Outcomes164
SecondaryNumber of Subjects With Positive FBB PET Scan

PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.

Time frame:
Visit 3 (up to 6 months after baseline evaluation)
Reported as:
Count of participants · Participants
Number of Subjects With Positive FBB PET Scan
ParticipantsSafety Analysis Set
Number of Subjects With Positive FBB PET Scan132
SecondaryNumber of Subjects With Negative FBB PET Scans

PET image interpretation was performed locally in each centre by readers who had undergone training for appropriate interpretation of scans. Scans were interpreted as either "positive" or "negative" according to the approved visual assessment method.

Time frame:
Visit 3 (up to 6 months after baseline evaluation)
Reported as:
Count of participants · Participants
Number of Subjects With Negative FBB PET Scans
ParticipantsSafety Analysis Set
Number of Subjects With Negative FBB PET Scans73
SecondaryNumber of Subjects With Contraindicated or Failed Lumbar Puncture

Number of subjects with contraindicated or failed LP (anticoagulant therapy, thrombocytopenia, lumbar puncture failed, spinal problems)

Time frame:
Visit 1 (baseline evaluation)
Reported as:
Count of participants · Participants
Number of Subjects With Contraindicated or Failed Lumbar Puncture
ParticipantsSafety Analysis Set
Number of Subjects With Contraindicated or Failed Lumbar Puncture45
SecondaryNumber of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician

Non-contributory CSF results (ambiguous CSF result, CSF result inconsistent with clinical information, uninterpretable CSF result for technical reasons)

Time frame:
Visit 1 (baseline evaluation)
Reported as:
Count of participants · Participants
Number of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician
ParticipantsSafety Analysis Set
Number of Subjects With Available CSF Analysis But Results Considered as Non-contributory by the Clinician87
SecondaryNumber of Subjects Who Refused Lumbar Puncture.
Time frame:
Visit 1 (baseline evaluation)
Reported as:
Count of participants · Participants
Number of Subjects Who Refused Lumbar Puncture.
ParticipantsSafety Analysis Set
Number of Subjects Who Refused Lumbar Puncture.75

Adverse events

Collected over Adverse events were captured for up to 7 days after the PET scan procedure.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Analysis Set0/205 (0%)1/205 (0.5%)21/205 (10.2%)
Most frequent serious events
Most frequent serious events
EventSafety Analysis Set
Cerebellar infarctNervous system disorders1/205
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSafety Analysis Set
Injection Site ParaesthesiaGeneral disorders5/205
Injection Site PainGeneral disorders4/205
Injection Site HaematomaGeneral disorders2/205
GlaucomaEye disorders1/205
NauseaGastrointestinal disorders1/205
FatigueGeneral disorders1/205
InflammationGeneral disorders1/205
DehydrationMetabolism and nutrition disorders1/205
Polymyalgia RheumaticaMusculoskeletal and connective tissue disorders1/205
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/205

Baseline characteristics

All subjects who received any amount of florbetaben were included in the safety analysis set.

Age, Continuous
Age, Continuous(years)Neuraceq (Florbetaben 18F) PET Scan
Mean70.9 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Neuraceq (Florbetaben 18F) PET Scan
Female102
Male103
08

Study locations

1 site
  • Coordinating center (Hôpital de La Timone) and 18 associated centers in France
    Marseille, 13385, France
09

References and documents

Publications

  • Ceccaldi M, Jonveaux T, Verger A, Krolak-Salmon P, Houzard C, Godefroy O, Shields T, Perrotin A, Gismondi R, Bullich S, Jovalekic A, Raffa N, Pasquier F, Semah F, Dubois B, Habert MO, Wallon D, Chastan M, Payoux P; NEUUS in AD study group; Stephens A, Guedj E. Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimers Dement. 2018 Mar;14(3):293-305. doi: 10.1016/j.jalz.2017.09.009. Epub 2017 Nov 4. PubMed 29107051 ↗

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Sep 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2016
First posted
Feb 12, 2016
Start
Oct 2015
Primary completionActual
Sep 2016
CompletionActual
Nov 2016
Results first posted
Nov 2, 2018
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Piramal Imaging Limited→Lantheus Biosciences Ltd.
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Sponsor Piramal Imaging Limited→Lantheus Biosciences Ltd.
    + 3 other changes: identifiers, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT02681172
Responsible party
Sponsor
First posted
Feb 12, 2016
Start date
Oct 2015
Primary completion
Sep 2016
Completion
Nov 2016
Results posted
Nov 2, 2018
Last update
Oct 9, 2026

Study contacts

Mathieu Ceccaldi, Prof. MD.
principal investigator · Hôpital de La Timone, Marseille, France
Eric Guedj, Prof.
principal investigator · Hôpital de la Timone, Marseille, France

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florbetaben f-18

Start the discussion